Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
The Decline of Medicare Reimbursement in Clinical Pathology
View through CrossRef
Abstract
Introduction/Objective
Access to clinical pathology services nationwide is threatened by the lack of an annual inflationary update for physician reimbursement from the Centers for Medicare & Medicaid Services (CMS). Most recently, the 2024 Medicare Physician Fee Schedule (MPFS) implemented an overall 2.0% reduction in pathology reimbursement. The effects of recent inflationary trends on clinical pathology physician reimbursement are unknown. Thus, our study sought to analyze trends in Medicare reimbursement rates from 2004 to 2024 for clinical pathology procedures.
Methods/Case Report
The Physician Fee Schedule Look-Up Tool from the CMS was queried for the top 30 CPT codes utilized, and physician reimbursement data extracted. Monetary data was subsequently adjusted for inflation utilizing the Consumer Price Index and reported in 2024 US dollars. The average annual and total percent change in reimbursement were calculated for included procedures. A subset analysis was conducted to assess physician pathology clinical consultation services average annual and total percent change in reimbursement pre- and post- 2022 MPFS Update. The compound annual growth rate (CAGR) was calculated using 2024 and 2000 inflation- adjusted monetary data.
Results (if a Case Study enter NA)
Prior to adjusting for inflation, the average physician reimbursement decreased by 6.8% from 2004 to 2024 for included clinical pathology CPT codes. After adjusting for inflation, the average physician reimbursement decreased by 44.0% for included CPT codes. The greatest decrease in reimbursement observed from 2004 to 2024 was for flow cytometry interpretation, 2-8 minutes at 69.5% ($114.44 to $34.95) followed by flow cytometry interpretation, 9-15 minutes at 57.8% ($142.77 to $60.25) and flow cytometry interpretation, >16 minutes at 56.6% ($188.05 to $81.55). The average CAGR was -2.86%. Prior to adjusting for inflation, the average physician reimbursement for clinical pathology consultation services pre-2022 decreased by 0.9%, and when adjusted for inflation, decreased by 30.0%. Post-2022 MPFS revision, the average physician reimbursement for clinical pathology consultation services decreased by 3.5%, and when adjusted for inflation, decreased by 12.2%. The average CAGR pre-2022 was -2.0% and post-2022 was -4.3%.
Conclusion
Medicare physician reimbursement for common clinical pathology procedures is decreasing at an untenable rate annually. It is critical that policymakers understand these trends to ensure continued access to quality clinical pathology care at healthcare institutions.
Oxford University Press (OUP)
Title: The Decline of Medicare Reimbursement in Clinical Pathology
Description:
Abstract
Introduction/Objective
Access to clinical pathology services nationwide is threatened by the lack of an annual inflationary update for physician reimbursement from the Centers for Medicare & Medicaid Services (CMS).
Most recently, the 2024 Medicare Physician Fee Schedule (MPFS) implemented an overall 2.
0% reduction in pathology reimbursement.
The effects of recent inflationary trends on clinical pathology physician reimbursement are unknown.
Thus, our study sought to analyze trends in Medicare reimbursement rates from 2004 to 2024 for clinical pathology procedures.
Methods/Case Report
The Physician Fee Schedule Look-Up Tool from the CMS was queried for the top 30 CPT codes utilized, and physician reimbursement data extracted.
Monetary data was subsequently adjusted for inflation utilizing the Consumer Price Index and reported in 2024 US dollars.
The average annual and total percent change in reimbursement were calculated for included procedures.
A subset analysis was conducted to assess physician pathology clinical consultation services average annual and total percent change in reimbursement pre- and post- 2022 MPFS Update.
The compound annual growth rate (CAGR) was calculated using 2024 and 2000 inflation- adjusted monetary data.
Results (if a Case Study enter NA)
Prior to adjusting for inflation, the average physician reimbursement decreased by 6.
8% from 2004 to 2024 for included clinical pathology CPT codes.
After adjusting for inflation, the average physician reimbursement decreased by 44.
0% for included CPT codes.
The greatest decrease in reimbursement observed from 2004 to 2024 was for flow cytometry interpretation, 2-8 minutes at 69.
5% ($114.
44 to $34.
95) followed by flow cytometry interpretation, 9-15 minutes at 57.
8% ($142.
77 to $60.
25) and flow cytometry interpretation, >16 minutes at 56.
6% ($188.
05 to $81.
55).
The average CAGR was -2.
86%.
Prior to adjusting for inflation, the average physician reimbursement for clinical pathology consultation services pre-2022 decreased by 0.
9%, and when adjusted for inflation, decreased by 30.
0%.
Post-2022 MPFS revision, the average physician reimbursement for clinical pathology consultation services decreased by 3.
5%, and when adjusted for inflation, decreased by 12.
2%.
The average CAGR pre-2022 was -2.
0% and post-2022 was -4.
3%.
Conclusion
Medicare physician reimbursement for common clinical pathology procedures is decreasing at an untenable rate annually.
It is critical that policymakers understand these trends to ensure continued access to quality clinical pathology care at healthcare institutions.
Related Results
Optimisation of RIZIV – INAMI lump sums for incontinence
Optimisation of RIZIV – INAMI lump sums for incontinence
LIST OF FIGURES 8 -- LIST OF TABLES 10 -- LIST OF ABBREVIATIONS 13 -- SCIENTIFIC REPORT 16 -- 1 GENERAL INTRODUCTION 16 -- 1.1 AIM OF THE STUDY 16 -- 1.2 SCOPE 17 -- 1.3 REPORT OUT...
Medicare+Choice Appeal Procedures: Reconciling Due Process Rights and Cost Containment
Medicare+Choice Appeal Procedures: Reconciling Due Process Rights and Cost Containment
By signing the Balanced Budget Act of 1997 (BBA) on August 5, 1997, President Clinton made the most significant changes to Medicare, since its inception in 1965, by adopting market...
Proposed Physician Payment Schedule for 2013:
Guarded Prognosis for Interventional Pain
Management
Proposed Physician Payment Schedule for 2013:
Guarded Prognosis for Interventional Pain
Management
As happens every year, on July 1, 2012, the Centers for Medicare and Medicaid Services issued
a proposed policy and payment rate for services furnished under the Medicare physician...
Forensic Pathology Fellowship Training Positions and Subsequent Forensic Pathology Work Effort of past Forensic Pathology Fellows
Forensic Pathology Fellowship Training Positions and Subsequent Forensic Pathology Work Effort of past Forensic Pathology Fellows
The purpose of this study is to document the number of accredited, funded, and filled forensic pathology fellowship positions in the United States and to document the subsequent wo...
Skin TDP-43 pathology as a candidate biomarker for predicting amyotrophic lateral sclerosis decades prior to motor symptom onset
Skin TDP-43 pathology as a candidate biomarker for predicting amyotrophic lateral sclerosis decades prior to motor symptom onset
Abstract
The recognition that disease-associated proteinopathies can manifest in peripheral organs outside the central nervous system preceding the onset of neurologica...
One-Year Outcomes of Diabetes Self-Management Training Among Medicare Beneficiaries Newly Diagnosed With Diabetes
One-Year Outcomes of Diabetes Self-Management Training Among Medicare Beneficiaries Newly Diagnosed With Diabetes
Background:
Diabetes is highly prevalent among Medicare beneficiaries, resulting in costly health care utilization. Strategies to improve health outcomes, such as disea...
Use of Medicare’s Diabetes Self-Management Training Benefit
Use of Medicare’s Diabetes Self-Management Training Benefit
Medicare began reimbursing for outpatient diabetes self-management training (DSMT) in 2000; however, little is known about program utilization. Individuals diagnosed with diabetes ...
Proposal for a Value-Based Agreement to Reimburse Anti-obesity Medicines in Traditional Medicare
Proposal for a Value-Based Agreement to Reimburse Anti-obesity Medicines in Traditional Medicare
Anti-obesity medicines (AOMs), such as glucagon-like peptide-1 (GLP-1) agonists, hold great promise for slowing the chronic disease epidemic in the United States. Treatment with se...